Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.21 as of Sunday, July 26, 2026.
Forward PE Ratio (17.21) = Close Price ($76.01) / Consensus Forward EPS ($4.42)
FORWARD PE RATIO
17.21
SECTOR MEDIAN · HEALTHCARE
18.38
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-6.39%
vs the sector median at left
Hologic, Inc.
Market Cap
$16.97B
Forward PE Ratio
17.21
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 17.21 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.79B | 34.28 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.67B | 10.76 |
| DaVita Inc. (DVA)vs › | $15.11B | 15.82 |
| Viatris Inc. (VTRS)vs › | $20.08B | 7.03 |
| The Cooper Companies, Inc. (COO)vs › | $13.71B | 15.17 |
| Solventum Corporation (SOLV)vs › | $13.51B | 11.91 |
| STERIS plc (STE)vs › | $20.86B | 20.99 |
| Moderna, Inc. (MRNA)vs › | $21.45B | N/A |
| Revvity, Inc. (RVTY)vs › | $12.32B | 21.08 |
Trailing P/E
31.7
reported TTM EPS
Forward P/E
17.2
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.42 implies +84.2% EPS growth vs the reported trailing $2.40.
At today's $76.01 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-09-27 | $4.42 | $4.28 – $4.56 | 10 | 17.2x |
| 2027-09-27 | $4.80 | $4.50 – $5.08 | 7 | 15.8x |
| 2028-09-27 | $5.17 | $4.46 – $5.88 | 5 | 14.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
